Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Resolves Long-standing Competition with Boston Scientific Corporation Over Rights to Cardiovascular Gene Therapy in the U.S. and Europe

Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy Read More

An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website.  The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations. Read More

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at Read More

Last year, industry specialist GlobalData released a report estimating the global diabetic foot ulcer therapeutics market to be valued at $1.15 billion in 2010 with expectations of growth to $2.28 billion by 2017.  A recent article by BBC News called today’s diabetic foot care “appalling” and leading to “an increased risk of having a foot amputated.”  With their Excellagen product, Cardium Therapeutics (NYSE MKT: CXM), a company in the same industry as Impax Laboratories Inc. (NASDAQ: IPXL) and Osiris Therapeutics Inc. (NASDAQ: OSIR), Read More

It’s been a busy several weeks for Cardium Therapeutics (NYSE MKT: CXM) as industry attention and investor buzz continues to build around regenerative medicine companies. Generx®, Cardium’s flagship gene therapy product candidate, is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. In March 2012, Cardium initiated its Phase 3 registration clinical trial in Russia which is expected to enroll approximately 100 patients at up to eight leading cardiovascular centers. The San Diego Biotechnology Read More

In their latest interview, www.ceocfointerviews.com spent some time with Cardium Therapeutics (NYSE MKT: CXM) CEO and Chairman Christopher J. Reinhard.  The article title, “With their Regenerative Medicine Product Generx® for Coronary Artery Disease in Phase 3 Registration Study for International Markets, Cardium Therapeutics Inc. is Leading the Evolution of a Revolution” can be seen on the CEO/CFO Interviews website at: Read More

Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics. Read More